Sanofi is resetting its footprint and realigning resources in India, hoping to “crack the code” in an ultra-competitive market where segments like diabetes appear set for significant new product activity.
The French multinational’s four-pillar approach includes maximizing the potential of its existing established portfolio either via partnerships that can expand the reach of some of these bread-and-butter therapies into India’s vast interiors or then directly in strongholds like the diabetes segment and in parallel leveraging global and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?